logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme, Veracyte Announce U.S. Availability Of Afirma Thyroid FNA Analysis

Genzyme, a Sanofi company (SNY), and Veracyte, Inc.,said Monday that the Afirma Thyroid FNA Analysis, an innovative approach for improved thyroid nodule diagnosis, is now available to patients across the United States.

The Afirma Thyroid FNA Analysis combines expert cytopathology assessment of thyroid nodule fine needle aspiration samples, with the Afirma Gene Expression Classifier, a novel genomic test, used to resolve inconclusive results and thus help patients whose nodules are actually benign avoid unnecessary surgery.

Two independent clinical studies to date have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as "benign" with the same degree of accuracy as a benign cytopathology diagnosis.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Come weekends and the ride sharing company Lyft in association with the beer brand Budweiser will offer free travel for short distances. The program is aimed at discouraging drunk driving on holidays. The offer of 150,000 free trips will be available in 10 states, all through the year. Chinese Internet giant Baidu, Inc. on Wednesday announced the release of Apollo 1.5, the second generation of its Apollo open-source autonomous vehicle software. The company also said it plans to set up a 10 billion yuan, or $1.5 billion Apollo self-driving car fund to invest in 100 autonomous driving projects in the next three years. Facebook Inc. said it is tightening controls on its advertising targeting policies and tools after a ProPublica expose last week found that advertisers on the social media site were able to target users interested in anti-Semitic topics. The company clarified that it has long had a firm policy against hate on Facebook.
comments powered by Disqus
Follow RTT